This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vernalis Group plc
Drug Names(s): AS111793
Description: V85546 is a selective MMP 12 (macrophage elastase) inhibitor.
Deal Structure: V85546 had been developed by Serono under a collaboration initiated in 2000.
In October 2008, following the merger of Merck KGA and Serono, Vernalis regained all rights to a portfolio of compounds targeting the treatment of inflammatory disease, including V85546. These compounds were originally part of a Licence, Development and Commercialization agreement between Vernalis and Serono. Vernalis's obligations back to Merck Serono are single-digit royalties.
Partners: Merck KGaA
Additional information available to subscribers only: